



THE WHITE HOUSE  
WASHINGTON

# COVID-19 Press Briefing


March 12, 2021



# The Vaccination Progress Report

7-day average daily doses administered by week as of 3/11/2021\*

Doses per day



\*7-day average from March 3 – March 9 was 2.2M



# Daily Change in COVID-19 Cases, US

January 22, 2020 – March 10, 2021

TOTAL Cases Reported Since 1/22/20

28,971,056

NEW Cases Reported to CDC on 3/10/21

56,586

Change in 7-Day Case Average

-11.2%


Current 7-Day Case Average (3/4/21 - 3/10/21)

54,639

Prior 7-Day Case Average (2/25/21 - 3/3/21)

61,538

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
<b>Current</b>	314,180 (1/8/21)	249,378 (1/11/21)
<b>2<sup>nd</sup> Peak</b>	75,192 (7/17/20)	67,277 (7/23/20)
<b>1<sup>st</sup> Peak</b>	42,597 (4/6/20)	31,933 (4/12/20)



\*7-day averages exclude historical cases reported retroactively by states



# New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 9, 2021

Patients Currently Hospitalized with COVID on 3/9/21

**35,983**

New Admissions on 3/9/21

**5,035**

Peak in New Admissions (1/5/21)

**18,009**

Change in 7-Day Average of New Admissions


**-11.0%**

Current 7-Day Average of New Admissions (3/3/21 - 3/9/21)

**4,889**

Prior 7-Day Average of New Admissions (2/24/21 - 3/2/21)

**5,494**



# Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 10, 2021

TOTAL Deaths Reported Since 1/22/2020

527,726

NEW Deaths Reported to CDC on 3/10/21

1,513

Change in 7-Day Death Average

-19.3%

Current 7-Day Death Average (3/4/21 - 3/10/21)


1,465

Prior 7-Day Death Average (2/25/21 - 3/3/21)

1,816

Forecasted Total Deaths by 4/3/21

547,000-571,000




● New Deaths — 7-Day Moving Average - New Deaths\*

\*7-day averages exclude historical cases reported retroactively by states





**WEAR A MASK**



**STAY 6 FEET APART**



**AVOID CROWDS**



**AVOID TRAVEL**




News Release

# Expert U.S. Panel Develops NIH Treatment Guidelines for COVID-19

*“Living document” updated often as new clinical data accrue*

■ [Covid19treatmentguidelines.nih.gov](https://www.covid19treatmentguidelines.nih.gov)



# Monoclonal Antibodies for Today's Discussion

---

- Tocilizumab – Anti-IL-6 Receptor Antibody (Genentech)

## Monoclonal Antibodies Directed Against SARS-CoV-2 Spike Protein

- Bamlanivumab – (Lilly)
- Etesevimab – (Lilly)
- VIR-7831 – (Vir/GSK)
- REGEN-COV Cocktail (Casirivimab + Imdevimab) (Regeneron)





# **Monoclonal Antibodies for COVID-19 Treatment**






## COVID-19 Treatment Guidelines

# **The COVID-19 Treatment Guidelines Panel's Statement on the Use of Tocilizumab for the Treatment of COVID-19**

- **The Panel recommends the use of tocilizumab (single intravenous dose of 8 mg/kg of actual body weight, up to 800 mg) in combination with dexamethasone (6 mg daily for up to 10 days) in certain hospitalized patients who are exhibiting rapid respiratory decompensation due to COVID-19.**





**CROI**

Conference on Retroviruses  
and Opportunistic Infections

March 6-10, 2021

Abstract 121

## **Bamlanivimab+Etesevimab for Treatment of COVID-19 in High-Risk Ambulatory Patients**

M Dougan et al.

- 1,035 patients with mild-to-moderate COVID-19 received 2800mg bamlanivimab + 2800mg etesevimab or placebo, within 3 days of laboratory diagnosis.
- 70% reduction in COVID-19-related hospitalization and death by any cause by Day 29 in patients who received bamlanivimab+etesevimab combination treatment





Press Release

March 10, 2021


## **Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19**

- Interim analysis of data from 583 patients enrolled in the COMET-ICE trial
- **85% reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy compared to placebo**



# **Monoclonal Antibodies for COVID-19 Prevention**





**CROI**

Conference on Retroviruses  
and Opportunistic Infections

March 6-10, 2021


Abstract 121

# **Bamlanivimab Prevents COVID-19 Morbidity and Mortality in Nursing Home Setting**

MS Cohen et al.

- **Bamlanivimab highly effective in reducing incidence of symptomatic COVID-19 and SARS-CoV-2 infection among nursing home residents; well tolerated**
  - 80% reduction in incidence of moderate or worse COVID-19 at 8 weeks compared to placebo





**CROI**

Conference on Retroviruses  
and Opportunistic Infections

March 6-10, 2021

Abstract 123

# **REGEN-COV Antibody Cocktail (Casirivimab With Imdevimab) for COVID-19 Prevention: Interim Results**

MP O'Brien et al.

- 409 individuals with household exposure to SARS-CoV-2 received single subcutaneous dose of REGEN-COV or placebo within 96 hours of household member testing positive
- **REGEN-COV provided 100% protection against symptomatic infection**
- REGEN-COV reduced overall infection by 50%
  - Those infected had 100-fold lower viral load and shorter duration of detectable viral RNA





THE WHITE HOUSE  
WASHINGTON

WH.GOV